Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | MPO | P05164 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31744580 | 0.84 | IDO1 (0.48) | TRPA1HTR1AGPR84HTR2ATRPM8 | |
| SCHEMBL31744570 | 0.84 | GPR84 (0.46) | HTR1AGPR84MPOHTR2ATRPM8 | |
| SCHEMBL31744648 | 0.82 | HTR1A (0.45) | TRPA1HTR1AGPR84MPOHTR2A | |
| SCHEMBL31744623 | 0.79 | IDO1 (0.47) | TRPA1HTR1AGPR84MPOHTR2A | |
| SCHEMBL27266032 | 0.76 | MAPK1 (0.58) | KMT2AMEN1 | |
| SCHEMBL31744595 | 0.75 | GPR84 (0.50) | HTR1AGPR84HTR2ATRPM8KMT2A | |
| SCHEMBL31744680 | 0.75 | IDO1 (0.50) | HTR1AGPR84HTR2ATRPM8KMT2A | |
| SCHEMBL31744649 | 0.75 | GPR84 (0.46) | GPR84HTR2ATRPM8KMT2AIDO1 | |
| SCHEMBL31744712 | 0.74 | IDO1 (0.49) | HTR1AGPR84HTR2ATRPM8IDO1 | |
| SCHEMBL31744608 | 0.74 | IDO1 (0.50) | TRPA1HTR1AGPR84MPOHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382269-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES | CFD RES CORPORATION (US) | 2025-12-18 | — | — | US | claimed |
| US-20250382269-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES | CFD RES CORPORATION (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382269-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES | CD14, MIF, NOD2 | TRPA1 1224/4885HTR1A 4485/4885GPR84 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.